Bendamustine for relapsed multiple myeloma (all ages)

Document first published:: 9 July 2020
Page updated:: 22 July 2020
Topic:: Commissioning, Medicine, Specialised commissioning
Publication type:: Policy or strategy, Report

Document

Clinical commissioning policy proposition: Bendamustine for relapsed multiple myeloma (all ages)

Clinical commissioning policy proposition: Bendamustine for relapsed multiple myeloma (all ages)

PDF
112 KB
15 pages

Document

CPAG summary report: Bendamustine for relapsed multiple myeloma (all ages)

CPAG summary report: Bendamustine for relapsed multiple myeloma (all ages)

PDF
58 KB
5 pages

Document

Equality impact assessment: Bendamustine for relapsed multiple myeloma (all ages)

Equality impact assessment: Bendamustine for relapsed multiple myeloma (all ages)

PDF
38 KB
2 pages

Document

Impact assessment: Bendamustine for relapsed multiple myeloma (all ages)

Impact assessment: Bendamustine for relapsed multiple myeloma (all ages)

PDF
128 KB
18 pages

Document

Evidence review: Bendamustine for relapsed multiple myeloma (all ages)

Evidence review: Bendamustine for relapsed multiple myeloma (all ages)

PDF
575 KB
34 pages

Document

Consultation: Bendamustine for relapsed multiple myeloma (all ages)

Consultation: Bendamustine for relapsed multiple myeloma (all ages)

PDF
48 KB
3 pages